Is there a subset of patients with preoperatively diagnosed N2 non-small cell lung cancer who might benefit from surgical resection?

Journal of Thoracic and Cardiovascular Surgery

Volumn 138, Issue 4, 2009, Pages 849-858

  Ratto, Giovanni B ^a   Costa, Roberta ^b   Maineri, Paola ^a   Alloisio, Antonella ^a   Bruzzi, Paolo ^a   Dozin, Beatrice ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b SS Antonio e Biagio   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DISEASE SEVERITY; FEMALE; HUMAN; KAPLAN MEIER METHOD; LOBECTOMY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM LYMPH NODE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL TIME; SYMPTOMATOLOGY;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; PNEUMONECTOMY; PROGNOSIS;

EID: 70349094789     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.03.017     Document Type: Article

References (36)

1. Andre F., Grunenwald D., Pignon J.P., Dujon A., Pujol J.L., Brichon P.Y., et al. Survival of patients with resected N2-NSCLC: evidence for a subclassification and implications. J Clin Oncol 18 (2000) 2981-2989
2. Robinson L.A., Ruckdeschel J.C., Wagner Jr. H., and Stevens C.W. American College of Chest Physicians. Treatment of non-small cell lung cancer-stage IIIA: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132 3 Suppl (2007) 243S-265S
3. Albain K.S., Swann R.S., and Rusch V.R. Phase III study of concurrent chemotherapy and radiotherapy (CT/RT) vs CT/RT followed by surgical resection for stage IIIA (pN2) non-small-cell lung cancer (NSCLC): outcomes update of North American Intergroup 0139 (RTOG 9309). [abstract]. Proc Am Soc Clin Oncol 23 suppl (2005) 7014 Abstract 7014
4. van Meerbeeck J.P., Kramer G.W., Van Schil P.E., Legrand C., Smit E.F., Schramel F., et al., European Organisation for Research and Treatment of Cancer-Lung Cancer Group. Randomized control trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer. J Natl Cancer Inst 99 (2007) 442-450
5. Watanabe Y., Shimizu J., Oda M., Hayashi Y., Watanabe S., Tatsuzawa Y., et al. Aggressive surgical intervention in N2 non-small cell cancer of the lung. Ann Thorac Surg 51 (1991) 253-261
6. Goldstraw P., Mannam G., Kaplan D., and Michail P. Surgical management of non-small-cell cancer with ipsilateral mediastinal node metastasis (N2 disease). J Thorac Cardiovasc Surg 107 (1994) 19-28
7. Ratto G.B., Mereu C., and Motta G. The prognostic significance of preoperative assessment of mediastinal lymph nodes in patients with lung cancer. Chest 93 (1988) 807-813
8. Shields T.W. The significance of ipsilateral mediastinal lymph node metastasis (N2 disease) in non-small cell carcinoma of the lung. J Thorac Cardiovasc Surg 99 (1990) 48-53
9. Pearson F., DeLarue N., Ilves R., Todd T.R., and Cooper J.D. Significance of positive superior mediastinal nodes identified at mediastinoscopy in patients with resectable cancer of the lung. J Thorac Cardiovasc Surg 83 (1982) 1-11
10. Goldstraw P. The practice of cardiothoracic surgeons in the perioperative staging on non-small cell lung cancer. Thorax 47 (1992) 1-3
11. Pearson F.G. Mediastinal adenopathy-the N2 lesion. In: DeLarue N.C., and Eschapasse H. (Eds). International trends in general thoracic surgery, vol. 1. Lung cancer (1985), WB Saunders, Philadelphia 104
12. Backer C.L., Shields T.W., Lockhart C.G., Vogelzang R., and LoCicero III J. Selective preoperative evaluation for possible N2 disease in carcinoma of the lung. J Thorac Cardiovasc Surg 93 (1987) 337-343
13. Martini N., and Flehinger B.J. The role of surgery in N2 lung cancer. Surg Clin North Am 67 (1987) 1037-1049
14. Suzuki K., Nagai K., and Yoshida J. The prognosis of surgically resected N2 non-small cell lung cancer: the importance of clinical N status. J Thorac Cardiovasc Surg 118 (1999) 145-153
15. Ruckdeshel J.C. Combined modalities therapy of non-small cell lung cancer. Semin Oncol 24 (1997) 429-439
16. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Stalpaert G., Nackaerts K.L., Lerut T.E., et al. Survival and prognostic factors in resected N2 non-small cell lung cancer: a study of 140 cases. Leuven Lung Cancer Group. Ann Thorac Surg 63 (1997) 1441-1450
17. Okada M., Tsubota N., Yoshimura M., Miyamoto Y., and Matsuoka H. Induction therapy for non-small cell lung cancer with involved mediastinal nodes in multiple stations. Chest 118 (2000) 123-128
18. Ichinose Y., Kato H., Koike T., Tsuchiya R., Fujisawa T., Shimizu N., et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer 34 (2001) 29-36
19. Keller S.M., Adak S., Wagner H., and Johnson D.H. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 70 (2000) 358-366
20. Prenzel K.L., Baldus S.E., Mönig S.P., Tack D., Sinning J.M., Gutschow C.A., et al. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes. Cancer 100 (2004) 1909-1917
21. Naruke T., Suemasu K., and Ishikawa K. Lymph node mapping and curability at various levels of metastasis in resected lung cancer. J Thorac Cardiovasc Surg 76 (1978) 832-839
22. Sawyer T.E., Bonner J.A., and Gould P.M. The impact of surgical adjuvant thoracic radiation therapy for patients with non-small cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer 80 (1997) 1399-1408
23. Mountain C.F. The biological operability of stage III non-small cell lung cancer. Ann Thorac Surg 40 (1985) 60-64
24. Vansteenkiste J.F., De Leyn P.R., Deneffe G.J., Lerut T.E., and Demedts M.G. Clinical prognostic factors in surgically treated stage IIIA N2 non-small cell lung cancer: analysis of the literature. Lung Cancer 19 (1998) 3-13
25. Sioris T., Järvenpää R., Kuukasjärvi P., Helin H., Saarelainen S., and Tarkka M. Comparison of computed tomography and systematic lymph node dissection in determining TNM and stage in non-small cell lung cancer. Eur J Cardiothorac Surg 23 (2003) 403-408
26. Roth J.A., Fossella F., Komaki R., Ryan M.B., Putnam Jr. J.B., Lee J.S., et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small cell lung cancer. J Natl Cancer Inst 86 (1994) 673-680
27. Rosell R., Gómez-Codina J., Camps C., Maestre J., Padille J., Cantó A., et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small cell lung cancer. N Engl J Med 330 (1994) 153-158
28. Depierre A., Milleron B., Moro-Sibilot D., Chevret S., Quoix E., Lebeau B., et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIA non-small cell lung cancer. J Clin Oncol 20 (2002) 247-253
29. Nagai K., Tsuchiya R., Mori T., Tada H., Ichinose Y., Koike T., et al. A randomized trial comparing induction chemotherapy followed by surgery with surgery alone for patients with stage IIIA N2 non-small cell lung cancer (JCOG 9209). J Thorac Cardiovasc Surg 125 (2000) 254-260
30. Pass H.I., Pogrebniak H.W., Steinberg S.M., Mulshine J., and Minna J. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Thorac Surg 53 (1992) 992-998
31. Bueno R., Richards W.G., Swanson S.J., Jaklitsch M.T., Lukanich J.M., Mentzer S.J., et al. Nodal stage after neoadjuvant therapy for stage IIIA lung cancer determines patient survival. Ann Thorac Surg 70 (2000) 1826-1831
32. Voltolini L., Luzzi L., Ghiribelli C., Paladini P., Di Bisceglie M., and Gotti G. Results of induction chemotherapy followed by surgical resection in patients with stage IIIA (N2) non-small cell lung cancer: the importance of the nodal down-staging after chemotherapy. Eur J Cardiothorac Surg 20 (2001) 1106-1112
33. Betticher D.C., Hsu Schmitz S.F., Tötsch M., Hansen E., Joss C., von Briel C., et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 21 (2003) 1752-1759
34. Albain K.S., Rusch V.W., Crowley J.J., Rice T.W., Turrisi III A.T., Weick J.K., et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 13 (1995) 1880-1892
35. Sawabata N., Keller S.M., Matsumura A., Kawashima O., Hirono T., Osaka Y., et al. The impact of residual multi-level N2 disease after induction therapy for non-small cell lung cancer. Lung Cancer 42 (2003) 69-77
36. De Leyn P., Stroobants S., De Wever W., et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol 24 (2006) 3333-3339